Interview: The Pace Quickens For Calliditas's Berger's Disease Candidate

A Phase III trial design change could result in quicker patient access for Calliditas’s product candidate for Berger’s disease, and boost the growth potential for the Swedish biotech.    

Lucander_Renee
Calliditas CEO Renee Aguiar-Lucander • Source: Calliditas

The past 12 months or so have seen Calliditas Therapeutics AB attract a Chinese partner, start a Phase III study of its lead product, and conduct a follow-on financing to its June 2018 IPO. All of this has improved business options for the Swedish biotech and, in particular, “the capital has given us flexibility,” noted Calliditas’s CEO, Renée Aguiar-Lucander.

But possibly of greater significance for Calliditas are recent changes to the design of the Phase III study of its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category